TherapeuticsMD (TXMD) Return on Capital Employed (2011 - 2026)

TherapeuticsMD's Return on Capital Employed history runs 15 years deep, the most recent figure standing at 11.72% for Q1 2026.

• Quarterly Return on Capital Employed rose 562.0% year-over-year to 11.72% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11.72% (up 562.0% YoY) and the FY2025 annual result came in at 13.12%, up 390.0% from the prior year.
• Return on Capital Employed was 11.72% for Q1 2026 at TherapeuticsMD, up from 13.15% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 446.57% in Q2 2022 and bottomed at 21.28% in Q4 2023.
• A 5-year average of 50.06% and a median of 11.16% in 2025 frame the typical range for Return on Capital Employed.
• Annual changes were most pronounced in 2022 — Return on Capital Employed surged 52966 bps — and 2023, when it plunged 37849 bps.
• TherapeuticsMD's Return on Capital Employed stood at 1.82% in 2022, then tumbled by 1268 bps to 21.28% in 2023, then climbed by 21 bps to 16.8% in 2024, then gained by 22 bps to 13.15% in 2025, then gained by 11 bps to 11.72% in 2026.
• Business Quant data shows TXMD's Return on Capital Employed at 11.72% in Q1 2026, 13.15% in Q4 2025, and 10.37% in Q3 2025.